Cargando…
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Background: In COVID-19 patients, aldosterone via angiotensin-converting enzyme-2 deregulation may be responsible for systemic and pulmonary vasoconstriction, inflammation, and oxidative organ damage. Aim: To verify retrospectively the impact of the mineralcorticoid receptor antagonist canrenone i.v...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564548/ https://www.ncbi.nlm.nih.gov/pubmed/32933039 http://dx.doi.org/10.3390/jcm9092943 |
_version_ | 1783595739701575680 |
---|---|
author | Vicenzi, Marco Ruscica, Massimiliano Iodice, Simona Rota, Irene Ratti, Angelo Di Cosola, Roberta Corsini, Alberto Bollati, Valentina Aliberti, Stefano Blasi, Francesco |
author_facet | Vicenzi, Marco Ruscica, Massimiliano Iodice, Simona Rota, Irene Ratti, Angelo Di Cosola, Roberta Corsini, Alberto Bollati, Valentina Aliberti, Stefano Blasi, Francesco |
author_sort | Vicenzi, Marco |
collection | PubMed |
description | Background: In COVID-19 patients, aldosterone via angiotensin-converting enzyme-2 deregulation may be responsible for systemic and pulmonary vasoconstriction, inflammation, and oxidative organ damage. Aim: To verify retrospectively the impact of the mineralcorticoid receptor antagonist canrenone i.v. on the need of invasive ventilatory support and/or all-cause in-hospital mortality. Methods: Sixty-nine consecutive COVID-19 patients, hospitalized for moderate to severe respiratory failure at Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca’ Granda Ospedale Maggiore Policlinico of Milan, received two different therapeutic approaches in usual care according to the personal skills and pharmacological management experience of the referral medical team. Group A (n = 39) were given vasodilator agents or renin–angiotensin–aldosterone system (RAAS) inhibitors and group B (n = 30) were given canrenone i.v. Results: Among the 69 consecutive COVID-19 patients, those not receiving canrenone i.v. (group A) had an event-free rate of 51% and a survival rate of 64%. Group B (given a mean dose of 200 mg/q.d. of canrenone for at least two days of continuous administration) showed an event-free rate of 80% with a survival rate of 87%. Kaplan–Meier analysis for composite outcomes and mortality showed log rank statistics of 0.0004 and 0.0052, respectively. Conclusions: The novelty of our observation relies on the independent positive impact of canrenone on the all-cause mortality and clinical improvement of COVID-19 patients ranging from moderate to severe diseases. |
format | Online Article Text |
id | pubmed-7564548 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75645482020-10-29 The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients Vicenzi, Marco Ruscica, Massimiliano Iodice, Simona Rota, Irene Ratti, Angelo Di Cosola, Roberta Corsini, Alberto Bollati, Valentina Aliberti, Stefano Blasi, Francesco J Clin Med Article Background: In COVID-19 patients, aldosterone via angiotensin-converting enzyme-2 deregulation may be responsible for systemic and pulmonary vasoconstriction, inflammation, and oxidative organ damage. Aim: To verify retrospectively the impact of the mineralcorticoid receptor antagonist canrenone i.v. on the need of invasive ventilatory support and/or all-cause in-hospital mortality. Methods: Sixty-nine consecutive COVID-19 patients, hospitalized for moderate to severe respiratory failure at Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca’ Granda Ospedale Maggiore Policlinico of Milan, received two different therapeutic approaches in usual care according to the personal skills and pharmacological management experience of the referral medical team. Group A (n = 39) were given vasodilator agents or renin–angiotensin–aldosterone system (RAAS) inhibitors and group B (n = 30) were given canrenone i.v. Results: Among the 69 consecutive COVID-19 patients, those not receiving canrenone i.v. (group A) had an event-free rate of 51% and a survival rate of 64%. Group B (given a mean dose of 200 mg/q.d. of canrenone for at least two days of continuous administration) showed an event-free rate of 80% with a survival rate of 87%. Kaplan–Meier analysis for composite outcomes and mortality showed log rank statistics of 0.0004 and 0.0052, respectively. Conclusions: The novelty of our observation relies on the independent positive impact of canrenone on the all-cause mortality and clinical improvement of COVID-19 patients ranging from moderate to severe diseases. MDPI 2020-09-11 /pmc/articles/PMC7564548/ /pubmed/32933039 http://dx.doi.org/10.3390/jcm9092943 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vicenzi, Marco Ruscica, Massimiliano Iodice, Simona Rota, Irene Ratti, Angelo Di Cosola, Roberta Corsini, Alberto Bollati, Valentina Aliberti, Stefano Blasi, Francesco The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients |
title | The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients |
title_full | The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients |
title_fullStr | The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients |
title_full_unstemmed | The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients |
title_short | The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients |
title_sort | efficacy of the mineralcorticoid receptor antagonist canrenone in covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564548/ https://www.ncbi.nlm.nih.gov/pubmed/32933039 http://dx.doi.org/10.3390/jcm9092943 |
work_keys_str_mv | AT vicenzimarco theefficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT ruscicamassimiliano theefficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT iodicesimona theefficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT rotairene theefficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT rattiangelo theefficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT dicosolaroberta theefficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT corsinialberto theefficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT bollativalentina theefficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT alibertistefano theefficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT blasifrancesco theefficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT vicenzimarco efficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT ruscicamassimiliano efficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT iodicesimona efficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT rotairene efficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT rattiangelo efficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT dicosolaroberta efficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT corsinialberto efficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT bollativalentina efficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT alibertistefano efficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients AT blasifrancesco efficacyofthemineralcorticoidreceptorantagonistcanrenoneincovid19patients |